116026-95-0

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
TFPyC is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals for its ability to contribute to the development of new compounds with therapeutic or pesticidal properties.
Used in Antifungal Applications:
TFPyC is used as an antifungal agent for its inhibitory effects on fungal pathogens, making it a potential candidate for the treatment of fungal infections.
Used in Research and Development:
TFPyC is utilized in research and development applications, particularly in the field of organic synthesis, where it aids in the creation of novel chemical entities, and in drug discovery processes, where it may contribute to the identification of new therapeutic agents.

InChI:InChI=1/C11H14N2O3/c1-11(2,3)16-10(15)13-9-6-12-5-4-8(9)7-14/h4-7H,1-3H3,(H,13,15)

Upstream product

• 7647-01-0 hydrogenchloride 
• 7732-18-5 water 
• 594-19-4 tert.-butyl lithium 
• 56700-70-0 3-(tert-butoxycarbonylamino)pyridine 
• 2591-86-8 N-Formylpiperidine 
• 180253-66-1 3-(tert-butyloxycarbonylamino)-4-methyl-pyridine 
• 3430-27-1 3-amino-4-methylpyridine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 949922-44-5 ethyl 1,7-naphthyridine-3-carboxylate 
• 55279-29-3 3-amino-pyridine-4-carbaldehyde 
• 486422-81-5 4-[(dimethylamino)methyl]pyridin-3-amine 
• 55234-64-5 2-oxo-1,2-dihydro-[1,7]naphthyridine-3-carboxylic acid ethyl ester 
• 250674-49-8 1,7-naphthyridine-3-carboxylic acid 
• 316155-99-4 2-tert-butoxycarbonylamino-8-(4'-nitro-biphenyl-4-ylmethyl)-5,8-dihydro-6H-[1,7]naphthyridine-7-carboxylic acid ethyl ester 
• 316155-91-6 8-(4-benzyloxy-benzyl)-2-tert-butoxycarbonylamino-8H-[1,7]naphthyridine-7-carboxylic acid ethyl ester 
• 316156-07-7 2-amino-8-(4'-amino-biphenyl-4-ylmethyl)-5,8-dihydro-6H-[1,7]naphthyridine-7-carboxylic acid tert-butyl ester 
• 316155-95-0 2-tert-butoxycarbonylamino-8-(4-hydroxy-benzyl)-5,8-dihydro-6H-[1,7]naphthyridine-7-carboxylic acid ethyl ester 
• 316156-03-3 8-(4'-amino-biphenyl-4-ylmethyl)-5,6,7,8-tetrahydro-[1,7]naphthyridin-2-ylamine 
• 316155-87-0 2-carboxy-(1,6)-naphthyridine 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS

The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, Q, U, V, W, X, Z, m, n, and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

TETRACYCLIC INHIBITORS OF JANUS KINASES

The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

SUBSTITUTED AZACHINAZOLINES HAVING AN ANTIVIRAL ACTION

The invention relates to substituted azachinazolines and methods for the production thereof. The invention also relates to the use of said azachinazolines for producing medicaments for the treatment and/or prophylaxis of diseases, especially for using as antiviral agents, especially against cytomegaloviruses.

Tyrosine kinase inhibitors

The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such

Inhibitors of Cyclic AMP Phosphodiesterase. 3. Synthesis and Biological Evaluation of Pyrido and Imidazolyl Analogues of 1,2,3,5-Tetrahydro-2-oxoimidazoquinazoline

Hybridization of structural elements of 1,2,3,5-tetrahydro-2-oxoimidazoquinazoline ring system common to the cyclic AMP (cAMP) phosphodiesterase (PDE) inhibitors lixazinone (RS-82856,1) and anagrelide (3) with complementary features of other PDE inhibitor cardiotonic agents prompted the design and synthesis of the title compounds 7a-d, 11, 12, and 13a,b.The necessary features of these compounds were determined within the framework of the proposed active-site models for the high affinity form of cAMP PDE inhibited by cGMP (type IV).Evaluation of these targets, both in vitro as inhibitors of platelet or cardiac type IV PDE or in vivo as inotropic agents in the pentobarbital-anesthetized dog model of congestive heart failure, showed that these structure possessed negligibly enhanced activities over the parent heterocyclic system, and remained significantly inferior to 1 in all respects.This difference is ascribed to the absence of the N-cyclohexyl-N-methylbutyramidyl-4-oxy side chain of 1.The proposal that the acidic lactam-type functionality, common to the type IV PDE inhibitor inotropic agents such as 4-6 and 8-10, mimics the polarizable cyclic phosphate moiety of cAMP suggested that the side chain of 1 may function as an effective surrogate for selected characteristics of the adenine portion of cAMP.However, the results of this study show that incorporation of adenine-like hydrogen-bonding functionalities common to other type IV PDE inhibitors into the 1,2,3,5-tetrahydro-2-oxoimidazoquinazoline system did not enhance activity to the levels observed for 1 analogues.These observations, coupled with the kinetic pattern of inhibition of type IV PDE observed for 1 and analogues, suggest that access to a secondary, lipophilic-tolerant binding site, possibly coincident with the adenine binding domain, and adjacent to the catalytic ribose-phosphate binding site of platelet and cardiac type IV PDE, is responsible for the increased potency of these compounds.